Rhizen Pharmaceuticals have entered into an exclusive, worldwide license agreement, with Novartis for the development and commercialization of Rhizen’s, inhaled dual PI3K - delta gamma inhibitor and its closely related compounds for various indications.
[adsense:336x280:8701650588]
Under the terms of the agreement, Rhizen will receive an upfront payment and is eligible to receive development, regulatory and sales milestones payments . In addition Rhizen is also eligible to receive tiered royalties on annual nets sales.
[adsense:468x15:2204050025]
The lead compound is a novel, potent, and selective dual PI3K - delta gamma inhibitor with demonstrated antiinflammatory and immuno - modulatory activity in pre - clinical systems and models representative of respiratory diseases. With a favorable ADME and PK profile and high therapeutic index in animals, the inhaled dua PI3K - delta gamma inhibitor holds promise in the treatment of human airway.
